Q4 2024 · 13F-HR
5AM Venture Management, LLCholdings as filed
Filed 2025-02-14 · accession 0001085146-25-001687
$419.1M
Reported value
31
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $76.2M | 18.2% | 4,408,379 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $36.7M | 8.75% | 1,629,765 | Common | SOLE |
| 83086J200 | SKYE | SKYE BIOSCIENCE INC | $28.1M | 6.69% | 9,913,168 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $27.5M | 6.57% | 596,660 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $23.7M | 5.66% | 2,353,304 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $22.4M | 5.35% | 1,027,711 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $17.9M | 4.27% | 478,972 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $15.3M | 3.65% | 797,600 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $15.3M | 3.65% | 282,313 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $15.3M | 3.65% | 2,927,915 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $14.1M | 3.37% | 736,595 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $13.9M | 3.32% | 830,945 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $13.6M | 3.24% | 5,405,404 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $13.1M | 3.12% | 170,000 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $13.1M | 3.12% | 939,298 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $12.6M | 3.00% | 497,270 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $7.8M | 1.87% | 1,050,000 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $7.6M | 1.82% | 189,593 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $7.1M | 1.69% | 6,361,723 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $4.7M | 1.13% | 357,733 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $4.6M | 1.10% | 165,000 | Common | SOLE |
| 810648105 | SCPH | SCPHARMACEUTICALS INC | $4.3M | 1.01% | 1,200,647 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $4.2M | 1.01% | 800,000 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $4.0M | 0.96% | 572,665 | Common | SOLE |
| 75120L100 | — | RALLYBIO CORP | $3.5M | 0.83% | 3,630,724 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $3.3M | 0.78% | 476,200 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $2.5M | 0.60% | 541,666 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $1.9M | 0.45% | 995,841 | Common | SOLE |
| 59045L106 | — | MERSANA THERAPEUTICS INC | $1.9M | 0.45% | 1,305,000 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $1.5M | 0.36% | 56,725 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $1.5M | 0.35% | 490,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.